STOCK TITAN
  1. Home
  2. News
  3. FDMT

4D Molecular Therapeutics, Inc. - FDMT STOCK NEWS

Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a clinical-stage gene therapy company dedicated to developing transformative medicines for serious, unmet medical conditions. Utilizing its proprietary Therapeutic Vector Evolution platform, the company designs novel adeno-associated virus (AAV) vectors to treat genetic diseases.

Core Business: 4DMT focuses on three primary therapeutic areas: Ophthalmology, Cardiology, and Pulmonology. In ophthalmology, intravitreal vectors are employed for treatments like 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Cardiology projects include 4D-310 for Fabry disease cardiomyopathy, while pulmonology efforts are highlighted by 4D-710 for cystic fibrosis.

Recent Achievements: The company has shown promising interim safety and efficacy data for 4D-310 in treating Fabry disease cardiomyopathy, with significant improvements in cardiac function, exercise capacity, and quality of life. For 4D-150, positive interim results from the PRISM clinical trial indicate its potential as a best-in-class treatment for wet AMD, leading to the initiation of a Phase 3 clinical trial in 2025.

Partnerships and Financial Condition: 4DMT has established strategic partnerships and recently secured substantial financing, bolstering its financial health. The company reported $589 million in cash equivalents by Q1 2024, sufficient to fund operations into the first half of 2027.

Innovative Pipeline: 4DMT’s product candidates, currently in clinical and preclinical stages, include 4D-175 for geographic atrophy, 4D-725 for A1AT deficiency, and additional CNS programs through gene editing partnerships. The company’s advanced manufacturing processes support the potential commercialization of these therapies.

Learn more at www.4DMT.com and follow on LinkedIn.

News

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

Rhea-AI Summary
4D Molecular Therapeutics (FDMT) announces a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden. The company will also provide a program update on Monday, February 5, 2024. The webcast will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial. The presentation of the interim results will also be available at the Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences clinical trial
-
News

4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that the U.S. FDA granted Rare Pediatric Disease Designation for aerosolized 4D-710, a treatment for cystic fibrosis lung disease. Promising clinical trial results showed significant CFTR expression levels and improved quality of life for patients. The company is also planning an interim data update and pivotal trial planning update for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
News

TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors

Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management
News

4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced clinical pipeline progress, partnership with Arbor Biotechnologies, and organizational updates. The company ended 2023 with $300 million in estimated cash, expecting to fund operations into H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
-
News

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) and Arbor Biotechnologies, Inc. (Arbor) have announced a strategic partnership to co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system (CNS) diseases with high unmet medical needs. The initial product candidate will target amyotrophic lateral sclerosis (ALS), with additional targets expected to be in diseases with high unmet needs in both rare and large patient populations. The costs and profits will be shared evenly between the two companies, and Arbor will lead the research, development, and commercialization efforts on the first product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
partnership
-
News

4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced the FDA granting RMAT designation for their genetic medicine candidate 4D-150 for wet age-related macular degeneration (wet AMD). The designation follows interim Phase 1 PRISM clinical data demonstrating safety, tolerability, and clinical activity. 4D-150 has potential to address unmet medical needs and reduce treatment burden for wet AMD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
none
News

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced the presentation of initial interim landmark data analysis from the Phase 2 PRISM clinical trial at the Angiogenesis, Exudation, and Degeneration 2024 Conference. The data will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the trial, on February 3, 2024. The trial focuses on 4D-150, a treatment for high need patients with neovascular age-related macular degeneration (nAMD). The company will also host a webcast to discuss the data and provide a program update for 4D-150.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences clinical trial
-
News

4DMT to Participate in Upcoming Investor Conferences

Rhea-AI Summary
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) announced their participation in the 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023, including a fireside chat and one-on-one meetings with the management team. The event will be webcasted and archived for up to a year on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences
-
News

4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) reported rapid advancements in the development of 4D-150 for wet age-related macular degeneration (wet AMD), including completing enrollment of PRISM Phase 2 Dose Expansion ahead of schedule, receiving PRIME designation from the European Medicines Agency, and presenting positive interim data from 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis. The company also gained alignment with FDA on the plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
earnings
News

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Rhea-AI Summary
4D Molecular Therapeutics announces interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for cystic fibrosis lung disease. The treatment was well tolerated with no inflammation observed in lung biopsies. CFTR expression significantly exceeded normal levels in all participants, showing durable clinical activity. FDA feedback on development path expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
clinical trial

FAQ

What is the current stock price of 4D Molecular Therapeutics (FDMT)?

The current stock price of 4D Molecular Therapeutics (FDMT) is $6.31 as of December 20, 2024.

What is the market cap of 4D Molecular Therapeutics (FDMT)?

The market cap of 4D Molecular Therapeutics (FDMT) is approximately 279.7M.

What is 4D Molecular Therapeutics' core business?

4DMT focuses on developing transformative gene therapy products for ophthalmology, cardiology, and pulmonology using proprietary AAV vectors.

What recent achievements has 4D Molecular Therapeutics accomplished?

The company has shown promising interim data for 4D-310 in Fabry disease cardiomyopathy and initiated a Phase 3 clinical trial for 4D-150 in wet AMD.

What are the key products in 4DMT's pipeline?

Key products include 4D-150 for wet AMD, 4D-310 for Fabry disease, 4D-710 for cystic fibrosis, and 4D-725 for A1AT deficiency.

How is 4DMT financially positioned?

4DMT reported $589 million in cash equivalents in Q1 2024, sufficient to fund operations into the first half of 2027.

What partnerships has 4DMT established?

4DMT has strategic partnerships in gene editing and other areas to advance its diverse product pipeline.

What is the Therapeutic Vector Evolution platform?

It's 4DMT's proprietary platform that employs directed evolution to create novel AAV vectors tailored for specific therapeutic applications.

What is 4D-150 and what does it treat?

4D-150 is a gene therapy product for treating wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Where can I find more information about 4D Molecular Therapeutics?

Visit their website at www.4DMT.com and follow them on LinkedIn for updates and further details.

What are the clinical-stage products in 4DMT’s pipeline?

4DMT has five clinical-stage products: 4D-150, 4D-310, 4D-710, 4D-725, and 4D-175.

What is the significance of 4D-310's interim data for Fabry disease?

The data show significant improvements in cardiac function, exercise capacity, and quality of life, indicating strong clinical activity and safety.

Stock FDMT logo
4D Molecular Therapeutics, Inc.

Nasdaq:FDMT

FDMT Rankings

#3592 Ranked by Market Cap
N/A Ranked by Dividends

FDMT Stock Data

279.68M
44.42M
3.91%
115.24%
16.93%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
EMERYVILLE